Rudman D, Chawla R K, Del Rio A E, Hollins B
J Clin Invest. 1974 Mar;53(3):868-74. doi: 10.1172/JCI107627.
Patient B. J. with chronic myelocytic leukemia excreted 0.5-1.1 g protein per day in the urine. Gel filtration on Sephadex G-75 showed about one-third of this protein to be in molecular weight range 20,000-40,000 (fraction BJC). BJC, prepared from 9 liters of urine by gel filtration, was chromatographed on carboxymethylcellulose. Two proteins were eluted from the resin in pure form (as shown by zone and immunoelectrophoresis) in yields representing 8 and 3 mg/liter of urine: BJC1 and BJC2. Their amino acid compositions were identical. BJC1 contained 61% carbohydrate (33% hexose, 11% sialic acid, 13% glucosamine, 5% galactosamine). BJC2 contained one-fourth to one-half as much of each carbohydrate. Molecular weight of BJC1 was estimated at 29,000 by gel filtration. Neither glycoprotein reacted with rabbit antiserum to normal human serum.Antiserum to BJC1 was made in the rabbit. Immunoelectrophoresis with this antiserum showed a faint precipitin line, corresponding in mobility to BJC1, in normal human plasma, and a stronger line in most leukemic plasmas. By immunodiffusion, BJC1 was not detectable in normal human urine, but a positive reaction occurred in the following conditions: leukemia, 64-72%; other types of disseminated neoplastic disease, 36-78%; regional ileitis, 45%; ulcerative colitis, 38%; tuberculosis, 33%; during the 1st wk after major surgery, 33%.BJC2 was found in the urine by immunoelectrophoresis in 10% of patients with neoplastic disease and was not observed in urine of other patients or in human plasma. Amino acid composition, carbohydrate content, and antigenic specificity indicate BJC1 is a previously unrecognized member of the system of normal human plasma glycoproteins. Like certain other glycoproteins, its plasma concentration frequently increases in patients with neoplastic disease, chronic inflammatory disease, or tuberculosis and after surgery. Because molecular weight is 29,000, increased plasma concentration readily causes its appearance in the urine.
患有慢性粒细胞白血病的患者B.J.每天尿中排出0.5 - 1.1克蛋白质。在Sephadex G - 75上进行凝胶过滤显示，该蛋白质约三分之一的分子量在20,000 - 40,000范围内（组分BJC）。通过凝胶过滤从9升尿液中制备的BJC在羧甲基纤维素上进行层析。两种蛋白质以纯形式从树脂上洗脱下来（通过区带电泳和免疫电泳显示），产率分别为每升尿液8毫克和3毫克：BJC1和BJC2。它们的氨基酸组成相同。BJC1含有61%的碳水化合物（33%己糖、11%唾液酸、13%氨基葡萄糖、5%半乳糖胺）。BJC2每种碳水化合物的含量为BJC1的四分之一到二分之一。通过凝胶过滤估计BJC1的分子量为29,000。这两种糖蛋白均不与兔抗正常人血清发生反应。用兔制备了抗BJC1血清。用该抗血清进行免疫电泳显示，在正常人血浆中出现一条微弱的沉淀线，其迁移率与BJC1对应，在大多数白血病血浆中出现一条更强的线。通过免疫扩散，在正常人尿液中检测不到BJC1，但在以下情况下出现阳性反应：白血病，64 - 72%；其他类型的播散性肿瘤疾病，36 - 78%；局限性肠炎，45%；溃疡性结肠炎，38%；结核病，33%；大手术后第1周，33%。通过免疫电泳在10%的肿瘤疾病患者尿液中发现了BJC2，在其他患者的尿液或人血浆中未观察到。氨基酸组成、碳水化合物含量和抗原特异性表明BJC1是正常人血浆糖蛋白系统中一个以前未被认识的成员。与某些其他糖蛋白一样，在肿瘤疾病、慢性炎症性疾病或结核病患者以及手术后，其血浆浓度经常升高。由于分子量为29,000，血浆浓度升高很容易导致其出现在尿液中。
